A randomized, open-label, multiple doses, crossover study to evaluate a pharmacokinetic drug interaction and safety of Candesartan free combination of Candesartan and Amlodipine and Candesartan monotherapy
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0001052
- Lead Sponsor
- Chong Kun Dang
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 24
Inclusion Criteria:
1.Healthy male volunteer is between 20 and 45 years of age(inclusive) at the pre-study(screening).
2.Volunteer who has 19kg/m² = BMI(Body Mass Index) = 26kg/m²
3.When volunteer in screening, Must include under the items.
a.100 mmHg = sitting SBP(systolic blood pressure) <140 mmHg
b.60 mmHg = sitting DBP(diastolic blood pressure) < 90 mmHg
c.45 bpm = Pulse < 95 bpm
4.Those who decided to join the clinical trials by themselves and to comply with the precautions written consent.
Exclusion Criteria:
1.A previous history or present of clinically significant liver, renal, gastro-intestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric, hemato-oncological, cardiovascular disease.
2.Have a gastrointestinal disease history that can affect drug absorption(Crohn's disease, Ulcers, Gastro-esophageal reflux disease, Gastritis, etc.) or surgery (except simple appendectomy or hernia surgery).
3.The history of clinically significant hypersensitivity reaction about Investigational drugs and foods.
4.The history of drug abuse or drug abuse showed a positive for urine drug test.
5.Taking drugs have received any other investigational drug within 90 days prior to the first dosing and metabolizing enzyme inducers or inhibitors such as barbitals within 30 days prior to the first dosing.
6.Whole blood donation within 60 days prior to the first dosing or plasma donation within 30 days prior to the first dosing.
7.Taking drugs that clinical trials expected to affect within 14days or taking food containing caffeine, grapefruit within 7days before the first dosing.
8.A heavy alcohol consumer(alcohol>3cup/day or 3times/week within last 1month)
9.A heavy smoker(cigarette>10cigarettes/day)
10.The subject has positive results of serum tests(Hepatitis B, C, HIV(Human immunodeficiency virus) Test, Syphilis).
11.Have the Liver enzyme levels(AST:Aspartate Transaminase, ALT:Alanin Transaminase) or Bilirubin, total results greater than 1.5 times the UNL(Upper Normal Limit).
12.Have the result of Creatinine clearance under than 80mL/min(Cockcroft-Gault equation applicable).
13.The result of 12-lead ECG(electrocardiography) in screening test is QTc>450msec.
14.An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AUCt,ss, Cmax,ss of Candesartan
- Secondary Outcome Measures
Name Time Method Tmax,ss of Candesartan